OVID - オ―ビッド・セラピュ―ティクス (Ovid Therapeutics Inc.)

OVIDのニュース

   EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer) - Stocks News Feed  2020/11/23 05:18:50 Stocks News Feed
Accepted 2020-11-23 00:18:50 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-20 Registration Form S-3 Document Format Files Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381 Ovid Therapeutics Inc. (Filer) CIK: 0001636651… Read More »EFFECT – Ovid Therapeutics Inc. (0001636651) (Filer)
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   L'étude ELEKTRA de Phase 2 évaluant le soticlestat (TAK-935/OV935) atteint son critère principal de réduction de la fréquence des crises chez les enfants atteints du syndrome de Dravet ou du syndrome de Lennox-Gastaut  2020/08/26 22:23:00 Business Wire
NEW YORK & OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") et Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), une société biopharmaceutique s'engageant à développer des médicaments qui transforment la vie des personnes atteintes de maladies neurologiques rares, annoncent ce jour des résultats positifs de l'étude ELEKTRA de Phase 2 randomisée évaluant soticlestat chez des enfants atteints du syndrome de Dravet (SD) ou du syndrome de Lennox-Gast
   Estudo ELEKTRA de Fase 2 do soticlestat (TAK-935/OV935) cumpre com o endpoint primário, reduzindo a frequência de convulsões em crianças com Síndrome de Dravet ou Síndrome de Lennox-Gastaut  2020/08/26 07:44:00 Business Wire
NOVA YORK (EUA) e OSAKA (Japão)--(BUSINESS WIRE)--A Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), uma empresa biofarmacêutica comprometida com o desenvolvimento de medicamentos que transformam a vida de pessoas com doenças neurológicas raras, anunciou hoje os resultados positivos do estudo ELEKTRA de Fase 2 randomizado do soticlestat em crianças com Síndrome de Dravet (SD) ou Síndrome de Lennox-Gastaut (SLG). O soticlest
   El estudio de fase 2 ELEKTRA de soticlestat (TAK-935/OV935) cumple el criterio de valoración principal de reducir la frecuencia de convulsiones en niños con síndrome de Dravet o síndrome de Lennox-Gastaut  2020/08/26 07:36:00 Business Wire
NUEVA YORK y OSAKA, Japón--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) («Takeda») y Ovid Therapeutics Inc. (NASDAQ: OVID) («Ovid»), una empresa biofarmacéutica comprometida con el desarrollo de medicamentos que transforman la vida de las personas con enfermedades neurológicas poco usuales, han anunciado hoy resultados preliminares positivos del estudio aleatorizado de fase 2 ELEKTRA de soticlestat en niños con síndrome de Dravet (SD) o síndrome de Lennox-Gastaut (
   EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer) - Stocks News Feed  2020/11/23 05:18:50 Stocks News Feed
Accepted 2020-11-23 00:18:50 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-20 Registration Form S-3 Document Format Files Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381 Ovid Therapeutics Inc. (Filer) CIK: 0001636651… Read More »EFFECT – Ovid Therapeutics Inc. (0001636651) (Filer)
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   L'étude ELEKTRA de Phase 2 évaluant le soticlestat (TAK-935/OV935) atteint son critère principal de réduction de la fréquence des crises chez les enfants atteints du syndrome de Dravet ou du syndrome de Lennox-Gastaut  2020/08/26 22:23:00 Business Wire
NEW YORK & OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") et Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), une société biopharmaceutique s'engageant à développer des médicaments qui transforment la vie des personnes atteintes de maladies neurologiques rares, annoncent ce jour des résultats positifs de l'étude ELEKTRA de Phase 2 randomisée évaluant soticlestat chez des enfants atteints du syndrome de Dravet (SD) ou du syndrome de Lennox-Gast
   Estudo ELEKTRA de Fase 2 do soticlestat (TAK-935/OV935) cumpre com o endpoint primário, reduzindo a frequência de convulsões em crianças com Síndrome de Dravet ou Síndrome de Lennox-Gastaut  2020/08/26 07:44:00 Business Wire
NOVA YORK (EUA) e OSAKA (Japão)--(BUSINESS WIRE)--A Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), uma empresa biofarmacêutica comprometida com o desenvolvimento de medicamentos que transformam a vida de pessoas com doenças neurológicas raras, anunciou hoje os resultados positivos do estudo ELEKTRA de Fase 2 randomizado do soticlestat em crianças com Síndrome de Dravet (SD) ou Síndrome de Lennox-Gastaut (SLG). O soticlest
   El estudio de fase 2 ELEKTRA de soticlestat (TAK-935/OV935) cumple el criterio de valoración principal de reducir la frecuencia de convulsiones en niños con síndrome de Dravet o síndrome de Lennox-Gastaut  2020/08/26 07:36:00 Business Wire
NUEVA YORK y OSAKA, Japón--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) («Takeda») y Ovid Therapeutics Inc. (NASDAQ: OVID) («Ovid»), una empresa biofarmacéutica comprometida con el desarrollo de medicamentos que transforman la vida de las personas con enfermedades neurológicas poco usuales, han anunciado hoy resultados preliminares positivos del estudio aleatorizado de fase 2 ELEKTRA de soticlestat en niños con síndrome de Dravet (SD) o síndrome de Lennox-Gastaut (
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   L'étude ELEKTRA de Phase 2 évaluant le soticlestat (TAK-935/OV935) atteint son critère principal de réduction de la fréquence des crises chez les enfants atteints du syndrome de Dravet ou du syndrome de Lennox-Gastaut  2020/08/26 22:23:00 Business Wire
NEW YORK & OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") et Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), une société biopharmaceutique s'engageant à développer des médicaments qui transforment la vie des personnes atteintes de maladies neurologiques rares, annoncent ce jour des résultats positifs de l'étude ELEKTRA de Phase 2 randomisée évaluant soticlestat chez des enfants atteints du syndrome de Dravet (SD) ou du syndrome de Lennox-Gast
   Estudo ELEKTRA de Fase 2 do soticlestat (TAK-935/OV935) cumpre com o endpoint primário, reduzindo a frequência de convulsões em crianças com Síndrome de Dravet ou Síndrome de Lennox-Gastaut  2020/08/26 07:44:00 Business Wire
NOVA YORK (EUA) e OSAKA (Japão)--(BUSINESS WIRE)--A Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), uma empresa biofarmacêutica comprometida com o desenvolvimento de medicamentos que transformam a vida de pessoas com doenças neurológicas raras, anunciou hoje os resultados positivos do estudo ELEKTRA de Fase 2 randomizado do soticlestat em crianças com Síndrome de Dravet (SD) ou Síndrome de Lennox-Gastaut (SLG). O soticlest
   El estudio de fase 2 ELEKTRA de soticlestat (TAK-935/OV935) cumple el criterio de valoración principal de reducir la frecuencia de convulsiones en niños con síndrome de Dravet o síndrome de Lennox-Gastaut  2020/08/26 07:36:00 Business Wire
NUEVA YORK y OSAKA, Japón--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) («Takeda») y Ovid Therapeutics Inc. (NASDAQ: OVID) («Ovid»), una empresa biofarmacéutica comprometida con el desarrollo de medicamentos que transforman la vida de las personas con enfermedades neurológicas poco usuales, han anunciado hoy resultados preliminares positivos del estudio aleatorizado de fase 2 ELEKTRA de soticlestat en niños con síndrome de Dravet (SD) o síndrome de Lennox-Gastaut (
   Phase-2-Studie ELEKTRA zu Soticlestat (TAK-935/OV935) erreicht primären Endpunkt: Reduktion der Anfallshäufigkeit bei Kindern mit Dravet-Syndrom oder Lennox-Gastaut-Syndrom  2020/08/26 02:41:00 Business Wire
NEW YORK und OSAKA, Japan--(BUSINESS WIRE)--Die Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda”) und Ovid Therapeutics Inc. (NASDAQ: OVID) („Ovid”), ein Biopharma-Unternehmen, das sich mit der Entwicklung von Medikamenten beschäftigt, die das Leben von Menschen mit seltenen neurologischen Erkrankungen verändern, gaben heute die ersten positiven Ergebnisse der randomisierten Phase-2-Studie ELEKTRA zu Soticlestat bei Kindern mit Dravet-Syndrom (DS) oder Lennox-Gastaut-Syndrom

calendar